Logo image of KTTA

PASITHEA THERAPEUTICS CORP (KTTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KTTA - US70261F2020 - Common Stock

1.17 USD
+0.01 (+0.86%)
Last: 12/24/2025, 7:42:58 PM
1.17 USD
0 (0%)
After Hours: 12/24/2025, 7:42:58 PM
Fundamental Rating

2

KTTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KTTA as it has an excellent financial health rating, but there are worries on the profitability. KTTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KTTA has reported negative net income.
KTTA had a negative operating cash flow in the past year.
KTTA had negative earnings in each of the past 5 years.
KTTA had a negative operating cash flow in each of the past 5 years.
KTTA Yearly Net Income VS EBIT VS OCF VS FCFKTTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

KTTA has a Return On Assets of -99.00%. This is in the lower half of the industry: KTTA underperforms 74.91% of its industry peers.
The Return On Equity of KTTA (-110.55%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -99%
ROE -110.55%
ROIC N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KTTA Yearly ROA, ROE, ROICKTTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KTTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KTTA Yearly Profit, Operating, Gross MarginsKTTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for KTTA has been increased compared to 1 year ago.
KTTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KTTA Yearly Shares OutstandingKTTA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
KTTA Yearly Total Debt VS Total AssetsKTTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

KTTA has an Altman-Z score of 1.85. This is not the best score and indicates that KTTA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.85, KTTA is doing good in the industry, outperforming 65.66% of the companies in the same industry.
There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.85
ROIC/WACCN/A
WACCN/A
KTTA Yearly LT Debt VS Equity VS FCFKTTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

KTTA has a Current Ratio of 4.02. This indicates that KTTA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.02, KTTA is in line with its industry, outperforming 48.11% of the companies in the same industry.
KTTA has a Quick Ratio of 4.02. This indicates that KTTA is financially healthy and has no problem in meeting its short term obligations.
KTTA has a Quick ratio of 4.02. This is comparable to the rest of the industry: KTTA outperforms 49.81% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 4.02
KTTA Yearly Current Assets VS Current LiabilitesKTTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.76% over the past year.
EPS 1Y (TTM)63.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KTTA Yearly Revenue VS EstimatesKTTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 100K 200K 300K 400K 500K
KTTA Yearly EPS VS EstimatesKTTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KTTA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KTTA Price Earnings VS Forward Price EarningsKTTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KTTA Per share dataKTTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KTTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PASITHEA THERAPEUTICS CORP

NASDAQ:KTTA (12/24/2025, 7:42:58 PM)

After market: 1.17 0 (0%)

1.17

+0.01 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13
Earnings (Next)03-23 2026-03-23
Inst Owners12.95%
Inst Owner Change103.68%
Ins Owners1.51%
Ins Owner Change7.92%
Market Cap26.08M
Revenue(TTM)N/A
Net Income(TTM)-13.49M
Analysts82.86
Price TargetN/A
Short Float %17.6%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 6.35
EV/EBITDA N/A
EPS(TTM)-5.21
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.55
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99%
ROE -110.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 4.02
Altman-Z 1.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1213.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.8%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.77%
OCF growth 3YN/A
OCF growth 5YN/A

PASITHEA THERAPEUTICS CORP / KTTA FAQ

What is the fundamental rating for KTTA stock?

ChartMill assigns a fundamental rating of 2 / 10 to KTTA.


What is the valuation status for KTTA stock?

ChartMill assigns a valuation rating of 0 / 10 to PASITHEA THERAPEUTICS CORP (KTTA). This can be considered as Overvalued.


What is the profitability of KTTA stock?

PASITHEA THERAPEUTICS CORP (KTTA) has a profitability rating of 0 / 10.


How financially healthy is PASITHEA THERAPEUTICS CORP?

The financial health rating of PASITHEA THERAPEUTICS CORP (KTTA) is 7 / 10.